Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma

Melanoma Research

Volumn 19, Issue 3, 2009, Pages 185-192

  Eisen, Tim ^a   Thomas, José ^b   Miller Jr , Wilson H ^c   Gore, Martin ^a   Wolter, Pascal ^b   Kavan, Petr ^c   López Martín, José A ^d   Lardelli, Pilar ^d  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c MCGILL UNIVERSITY   (Canada)

^d PHARMAMAR S A   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARNITINE; DACARBAZINE; DEXAMETHASONE; GLUCOCORTICOID; HEMOPOIETIC GROWTH FACTOR; METOCLOPRAMIDE; PLITIDEPSIN; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; DEHYDRODIDEMNIN B; DEPSIPEPTIDE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANAPHYLACTIC SHOCK; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRESS SYNDROME; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FLUSHING; FOLLOW UP; GASTRITIS; GROWTH REGULATION; HUMAN; HYPERSENSITIVITY; HYPOTENSION; INDUCED HYPOTENSION; INJECTION SITE REACTION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MELANOMA; MELENA; METASTASIS; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SKIN TUMOR; TUMOR RECURRENCE;

ADULT; AGED; DEPSIPEPTIDES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS;

EID: 67650687006     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32832bbde6     Document Type: Article

References (35)

1. GLOBOCAN 2000. Cancer incidence, mortality and prevalance worldwide, Version 1.0. IARC Cancer Base No.5. Lyon: IARC Press; 2001.
2. Sun W, Schuchter LM. Metastatic melanoma. Curr Treat Options Oncol 2001; 1:193-202.
3. Tarhini AA, Agarwala SS. Novel agents in development for the treatment of melanoma. Expert Opin Investig Drugs 2005; 14:885-892.
4. Tarhini AA, Agarwala SS. Interleukin-2 for the treatment of melanoma. Curr Opin Investig Drugs 2005; 6:1234-1239.
5. Kasper B, D'Hondt V, Vereecken P, Awada A. Novel treatment strategies for malignant melanoma: a new beginning? Crit Rev Oncol Hematol 2007; 62 :116-122.
6. Agarwala SS. Relevance and necessity of studies on second-line chemotherapy in melanoma. Onkologie 2004; 27:527-528.
7. Garcia-Fernandez LF, Losada A, Alcaide V, Alvarez AM, Cuadrado A, Gonzalez L, et al. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene 2002; 21:7533-7544.
8. Cuadrado A, Gonzalez L, Suarez Y, Martinez T, Munoz A. JNK activation is critical for Aplidin-induced apoptosis. Oncogene 2004; 23:4673-4680.
9. Muñoz MJ, Alvarez E, Martinez T, Gonzalez-Santiago L, Sasak H, Lepage D, et al. JNK activation as an in vivo marker of Aplidin [abstract]. AACR Annual Meeting 2007; 2007:5580.
10. Cuadrado A, Garcia-Fernandez LF, Gonzalez L, Suarez Y, Losada A, Alcaide V, et al. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J Biol Chem 2003; 278:241-250.
11. Gonzalez-Santiago L, Suarez Y, Zarich N, Muñoz-Alonso MJ, Cuadrado A, Martinez T, et al. Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ 2006; 13:1968-1981.
12. Biscardi M, Caporale R, Balestri F, Gavazzi S, Jimeno J, Grossi A. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Ann Oncol 2005; 16:1667-1674.
13. Taraboletti G, Poli M, Dossi R, Manenti L, Borsotti P, Faircloth GT, et al. Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer 2004; 90:2418-2424.
14. Broggini M, Marchini SV, Galliera E, Borsotti P, Taraboletti G, Erba E, et al. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 2003; 17 :52-59.
15. Straight AM, Oakley K, Moores R, Bauer AJ, Patel A, Tuttle RM, et al. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes. Cancer Chemother Pharmacol 2006; 57 :7-14.
16. Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR. In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer 1998; 78:739-744.
17. Bresters D, Broekhuizen AJ, Kaaijk P, Faircloth GT, Jimeno J, Kaspers GJ. In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development. Leukemia 2003; 17:1338-1343.
18. Anthoney A, Paz-Ares L, Twelves C. Phase I and pharmacokinetic (PK) study of Aplidin (APL) using a 24-h, weekly schedule [Abstract]. Proc Am Soc Clin Oncol 2000; 19:734.
19. Bowman A, Izquierdo MA, Jodrell D, Martinez M, Cicchella B, Jimeno J. Phase I clinical and pharmacokinetic (PK) study of the marine compound Aplidin (APL), administered as a 1 h weekly infusion [abstract]. Proc Am Soc Clin Oncol 2001; 20:476.
20. Faivre S, Chieze S, Delbaldo C, Ady-Vago N, Guzman C, Lopez-Lazaro L, et al. Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol 2005; 23:7871-7880.
21. Jimeno J, Lopez-Martin JA, Ruiz-Casado A, Izquierdo MA, Scheuer PJ, Rinehart K. Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs 2004; 15:321-329.
22. Ciruelos EM, Twelves C, Dominguez MJ, Mckay H, Anthony A, Castellanos D. Phase I clinical and pharmacokinetic study of the marine compound Aplidin (APL) administered as a 3 h infusion every 2 weeks [abstract]. Proc Am Soc Clin Oncol 2002; 21:422.
23. Maroun JA, Belanger K, Seymour L, Matthews S, Roach J, Dionne J, et al. Phase I study of Aplidine in a daily-5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Ann Oncol 2006; 17:1371-1378.
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216. (Pubitemid 30099779)
25. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18 :3558-3585.
26. Gralla R, Osoba D, Kris M, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999; 17:2971-2994.
27. National Cancer Institute Common Toxicity Criteria. Version 2.0, June 1, 1999. Available at: http://ctep.info.nih.gov. Accessed January 20, 2005.
28. Simon R. Optimal two-stage designs for clinical trials. Control Clin Trials 1989; 10:1-10.
29. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17 :2745-2751.
30. Riker AI, Radfar S, Liu S, Wang Y, Khong HT. Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opin Biol Ther 2007; 7:345-358.
31. Millward MJ, Bedikian AY, Conry RM, Gore ME, Pehamberger HE, Sterry W, et al. Randomized multinational phase 3 trial of decarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients with advanced malignant melanoma: analysis of long-term survival. J Clin Oncol (ASCO Annual Meeting Proceedings) 2004; 22:7505.
32. Saxman SB, Meyers ML, Chapman PB. A phase III multicenter randomized trial of DTIC, cisplatin, BCNU and tamoxifen versus DTIC alone in patients with metastatic melanoma. J Clin Oncol 1999; 18: A2068.
33. Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007; 24:CD005413.
34. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2003; 2:753-763.
35. Lev DC, Onn A, Melinkova VO, Miller C, Stone V, Ruiz M, et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol 2004; 22:2092-2100.